Cargando…
CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer’s Disease
Alzheimer’s disease (AD) is a scourge for patients, caregivers and healthcare professionals due to the progressive character of the disease and the lack of effective treatments. AD is considered a proteinopathy, which means that aetiological and clinical features of AD have been linked to the deposi...
Autores principales: | Bivona, Giulia, Iemmolo, Matilda, Ghersi, Giulio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179163/ https://www.ncbi.nlm.nih.gov/pubmed/37175935 http://dx.doi.org/10.3390/ijms24098230 |
Ejemplares similares
-
The Cytokine CX3CL1 and ADAMs/MMPs in Concerted Cross-Talk Influencing Neurodegenerative Diseases
por: Iemmolo, Matilda, et al.
Publicado: (2023) -
High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer’s Disease Patients but Not in Non-Alzheimer’s Disease Dementia
por: Bivona, Giulia, et al.
Publicado: (2022) -
Microglial Activation and Priming in Alzheimer’s Disease: State of the Art and Future Perspectives
por: Bivona, Giulia, et al.
Publicado: (2023) -
CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection
por: Chen, Peiqing, et al.
Publicado: (2016) -
Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
por: Perea, Juan R., et al.
Publicado: (2018)